Global Blood Therapeutics (GBT) Data 'Exceeded Our High Expectations' - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Global Blood Therapeutics (GBT) Gains on Positive Results from Ongoing Sickle Cell Drug Trial
June 10, 2016 9:07 AM EDTGlobal Blood Therapeutics (NASDAQ: GBT) is gaining 21% pre-open trade after the company... More
Global Blood Therapeutics (GBT) Announces New Results from Ongoing Phase 1/2 GBT440-001 Study in Sickle Cell Disease
June 10, 2016 8:01 AM EDTGlobal Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced new results from its ongoing Phase 1/2 GBT440-001 study in sickle cell disease (SCD) that further support the company's plans to develop GBT440 as a potential disease-modifying therapy for SCD. The data being presented today at the European Hematology Association's (EHA) 21st Congress in Copenhagen include a poster presentation of... More
